A new Federal Reserve FEDS Note finds a systematic link between Chinese industrial policy interventions and export growth. The 15 most policy-targeted sectors accounted for 76% of the increase in China’s aggregate trade surplus from 2017 to 2024.
Section 301 is a powerful tool for addressing foreign policies that distort global markets and disadvantage American producers. When foreign governments explicitly pursue overproduction and then export the resulting surplus into the United States, the effect is to displace domestic output and deter new investment in American manufacturing.
Section 301 actions against a particular country or group of countries are more likely to merely shift international supply chains as opposed to growing domestic productive output.
This Interim Agreement framework reflects a long overdue acknowledgment that essential medicine supply chains cannot be left to foreign dominance, particularly by India or an adversary like China.
To trade away aluminum and steel workers’ home market in exchange for padding Big Tech’s bottom line overseas is immoral and wrong. The Section 232 actions on aluminum and steel should be singularly focused on rebuilding domestic output across the supply chains, not used as leverage to help Google and Meta become even more profitable.
The Commerce Department should look to 7 C.F.R. Part 6 as a terrific example of how USDA has ensured that quota allocation benefits domestic manufacturers, not speculators.
CPA’s submission, “Ensuring U.S. Sovereignty in North American Trade,” concludes that the current trilateral USMCA framework binds two vastly different economies to one unenforceable system—with each reliant on the far larger U.S. consumer market.
There are very few things that Democrats and Republicans agree on. One of them is the need to support domestic shipbuilding beyond just military vessels.
America is finally getting serious about its dangerous dependence on foreign-made generic drugs.
The Trump administration’s Section 232 investigation into pharmaceutical imports is reportedly close to being final. The final investigation’s success will depend largely on whether or not the Commerce Department determines that there is a crisis in the generics industry — an issue that President Trump highlighted back in 2023.
